Voriconazole: Difference between revisions
From IDWiki
(→: added a few) |
(→) |
||
| Line 22: | Line 22: | ||
|} |
|} |
||
== Adverse |
== Adverse Drug Reactions == |
||
* Visual |
* Visual |
||
** Floaters etc that may improve with time |
** [[Adverse drug reaction::Floaters]] etc that may improve with time |
||
** Visual hallucinations |
** [[Adverse drug reaction::Visual hallucinations]] |
||
** Colour vision loss |
** [[Adverse drug reaction::Colour vision loss]] |
||
* Photosensitivity |
* [[Adverse drug reaction::Photosensitivity]] |
||
* Hepatotoxicity |
* [[Adverse drug reaction::Hepatotoxicity]] |
||
* QTc prolongation |
* [[Adverse drug reaction::QTc prolongation]] |
||
== Further Reading == |
== Further Reading == |
||
Revision as of 03:14, 18 February 2020
- Azole antifungal
- Indications include Alternaria, Blastomyces dermatitidis, Coccidioides immitis, Exophiala, Exserohilum, Fungal endocarditis, Histoplasma capsulatum, Rasamsonia
Therapeutic Drug Monitoring
- Measure trough within 7 days of starting, and at regular intervals or following dose adjustment
- Target trough > 1 mg/L for prophylaxis and treatment
| Trough (mcg/mL) | Recommendation |
|---|---|
| 0.0 to 0.6 | Increase dose by 100 mg and recheck trough on day 5 of new regimen |
| 0.7 to 0.9 | Increase dose by 50 mg and recheck trough on day 5 of new regimen |
| 1.0 to 4.0 | At target, no dose adjustment needed |
| 4.1 to 5.5 | Decrease dose by 50 mg and recheck trough on day 5 of new regimen |
| 5.6 to 7.9 | Hold dose. Follow daily trough levels, then restart when trough is ≤2.5 at a dose decreased by 100 mg. Recheck trough on day 5 of new regimen. |
| ≥8.0 | Hold dose. Follow daily trough levels, then restart when trough is ≤2.5 at a dose decreased by 50%. Recheck trough level on day 5 of new regimen. |
Adverse Drug Reactions
- Visual
- Floaters etc that may improve with time
- Visual hallucinations
- Colour vision loss
- Photosensitivity
- Hepatotoxicity
- QTc prolongation
Further Reading
- Voriconazole Dose Modification Guideline to Optimize Therapeutic Levels in Patients With Hematologic Malignancies. Open Forum Infect Dis. 2015(2)S1:810.
